PQUS0.240%
as of Sep 1
VRTX
GrowthVERTEX PHARMACEUTICALS INCORPORATED
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
Close · 3M
+29.67%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals4
Win rate100% (4/4)
Avg buy return+15.23%
PQUS · Weight increase · 2d
weight 0.230% → 0.250% (+0.020 pp)·stock up 15.8% in the 30 days before
Aug 21·entry $548.05·now $557.96Fresh
+1.81%
since Aug 21
PQUS · Weight increase · 2d
weight 0.230% → 0.280% (+0.050 pp)·stock down 4.2% in the 30 days before
Jul 31·entry $477.10·now $557.96Chased
+16.95%
since Jul 31
PQUS · Weight increase · 2d
weight 0.260% → 0.280% (+0.020 pp)·stock up 10.2% in the 30 days before
Jun 25·entry $480.18·now $557.96Chased
+16.20%
since Jun 25
PQUS · Weight increase · 2d
weight 0.250% → 0.270% (+0.020 pp)·stock up 4.5% in the 30 days before
Jun 7·entry $442.96·now $557.96Chased
+25.96%
since Jun 7
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.